A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R
lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase
(phase IIb).